UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
______________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 24, 2015
______________
CHINA GEWANG BIOTECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
______________
| | |
Nevada | 0-54451 | 42-1769584 |
(State or Other Jurisdiction | (Commission | (I.R.S. Employer |
of Incorporation) | File Number) | Identification No.) |
Xita 23C, Star International, No. 8 Jinsui Road, Pearl River New Town,
Guangzhou Province, P.R. China 510623
(Address of Principal Executive Office) (Zip Code)
86-024-2397-4663
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 4.01
Changes in Registrant’s Certifying Accountant.
On March 24, 2015, China Gewang Biotechnology, Inc. retained the firm of Wei, Wei & Co., LLP to serve as its principal independent accountant. At no time during the past two fiscal years or any subsequent period prior to March 24, 2015 did China Gewang Biotechnology, Inc. consult with Wei, Wei & Co., LLP regarding any of the enumerated items described in Item 304(a)(1)(iv) of Regulation S-K, any "reportable event,” as described in Item 304(a)(1)(v) of Regulation S-K, or the type of audit opinion that might be rendered for China Gewang Biotechnology, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| | |
| China Gewang Biotechnology, Inc. |
| | |
Date: April 20, 2015 | By: | /s/ Shili Zhang Shili Zhang, Chief Executive Officer |
2
